Uzedy Demonstrates Reduced Relapse Risk in Schizophrenia Patients
核心洞察
New data presented at the ECNP Congress show Uzedy, a risperidone extended-release injectable, significantly reduces relapse risk in adults with schizophrenia (搜索) compared to placebo.
Pharmacokinetic analysis suggests switching to Uzedy 4 weeks after the final dose of once-monthly RBP-7000 results in comparable drug exposure.
Simulation models support switching to Uzedy at 100 mg (once-monthly) or 200 mg (once-every-2-months) from 120 mg of once-monthly RBP-7000.
New data presented at the 37th Annual European College of Neuropsychopharmacology (ECNP) Congress in Milan highlight the efficacy of Uzedy, an extended-release injectable suspension of risperidone, in reducing the risk of relapse in adults with schizophrenia (搜索). The study findings offer insights into optimizing treatment strategies for this chronic mental disorder.
Uzedy, administered subcutaneously either monthly or bi-monthly, demonstrated a statistically significant reduction in relapse risk compared to placebo in patients with schizophrenia (搜索). This provides a valuable option for managing this condition, which affects approximately 1% of the global population and is characterized by recurring episodes of psychosis and functional decline.
Pharmacokinetic Study Details
A population pharmacokinetic analysis was conducted to predict drug exposure when switching patients from once-monthly RBP-7000 to Uzedy. Simulation models indicated that initiating Uzedy four weeks after the last injection of RBP-7000 resulted in comparable pharmacokinetic properties, both at initial exposure and at steady state. This finding supports the feasibility of transitioning patients between these medications with a relatively short washout period.
Specifically, the simulations suggested that Uzedy doses of 100 mg (once-monthly) or 200 mg (once-every-two-months) are comparable to 120 mg of once-monthly RBP-7000 in terms of pharmacokinetic profiles. This allows clinicians to choose a Uzedy dose that aligns with the patient's previous RBP-7000 regimen.
Clinical Implications
"This provides patients with different options and helps their professionals to match the needs and preferences of patients to the treatments that are available," said Dr. Christoph U. Correll, professor at the Institute of Behavioral Science, Feinstein Institutes for Medical Research (搜索). The flexibility in dosing regimens offered by Uzedy could improve treatment adherence and outcomes in patients with schizophrenia (搜索).
The current treatment landscape for schizophrenia (搜索) primarily involves antipsychotic medications, which can be administered orally or via long-acting injections. Long-acting injectables, like Uzedy, offer the advantage of improved adherence compared to oral medications, potentially reducing the risk of relapse and hospitalization. The study findings suggest that Uzedy is a valuable addition to the available treatment options for schizophrenia, offering a flexible and effective approach to relapse prevention.